Summary of Royalty Pharma Q1 2026 Earnings Call

1Key Financial Results and Metrics

Portfolio Receipts: Increased by 10% year-over-year.

Royalty Receipts: Grew by 13%, driven by strong performance from products like Tremfya, Voranigo, and Evrysdi.

Operating Costs: 3.9% of portfolio receipts, benefiting from cost savings due to the internalization transaction completed last May.

Net Interest Paid: $167 million for the quarter, reflecting the semiannual payment schedule.

Adjusted EBITDA: Portfolio cash flow amounted to $722 million.

Return on Invested Capital: 14.1% and return on invested equity at 19.7%.

Cash Position: $586 million in cash and equivalents, with total debt of $9.2 billion and leverage at 2.9x total debt to adjusted EBITDA.

2Strategic Updates and Business Highlights

Capital Deployment: Announced $1.25 billion in transactions across three therapies, with over $0.5 billion deployed in the quarter. Share repurchases totaled $50 million, and dividends were increased by 7%.

R&D Co-Funding: Significant focus on expanding partnerships with biopharma companies, with $1 billion in co-funding agreements signed with J&J and Teva.

Portfolio Expansion: Positive clinical results for Revolution Medicines' daraxonrasib and FDA approval for Denali's Avlayah were highlighted.

Leadership Enhancements: New hires in key positions to strengthen capabilities in Asia Pacific and artificial intelligence.

3Forward Guidance and Outlook

2026 Guidance Raised: Full-year portfolio receipts expected to range from $3.325 billion to $3.45 billion, up from previous estimates.

Royalty Growth: Anticipated growth in royalty receipts of 4% to 8%, despite the loss of exclusivity for Promacta and the launch of biosimilar Tysabri.

Q2 Guidance: Portfolio receipts projected between $740 million and $760 million.

4Bad News, Challenges, or Points of Concern

Declining Metrics: Notable year-over-year decline in milestone and other contractual receipts, expected to drop from $128 million in 2025 to approximately $60 million in 2026.

Arbitration Update: Ongoing arbitration with Vertex is now expected to conclude around mid-2027, which may create uncertainty.

Competitive Pressures: Concerns regarding the evolving landscape of the royalty market and potential impacts from consolidation among smaller players.

5Notable Q&A Insights

Derisking Future Targets: Management expressed confidence in meeting or exceeding the long-term target of approaching $5 billion in portfolio receipts by 2030, citing strong business momentum.

R&D Co-Funding vs. Traditional Royalties: Management indicated that while R&D co-funding could increase its share of capital deployment, the focus remains on product quality over the funding structure.

Market Dynamics: Questions about the impact of potential pricing strategies in international markets and the implications of recent consolidation among smaller royalty players were discussed, with management emphasizing their competitive advantages.

AI Implementation: Management highlighted ongoing investments in data and AI to enhance deal evaluation and operational efficiency, with a dedicated team now in place to drive these initiatives. Overall, Royalty Pharma reported a strong start to 2026, with solid financial performance and strategic initiatives aimed at expanding its market presence and capitalizing on emerging opportunities in the biopharma sector.